CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline
- Written by PR Newswire
![]() |
SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results.
Business Highlights
- CT053: completed enrollment for pivotal Phase II trial in China,...
Read more: CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline















